Finoriq research workspace
Immunovant, Inc. (IMVT) SEC Filings & Filing Highlights
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the. Review IMVT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Company
- Immunovant, Inc. (IMVT)
- Ticker
- IMVT
- Market Cap
- $8.2B
- Latest Price
- $39.91
- Industry
- Biotech & Pharma
Immunovant, Inc. (IMVT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Immunovant, Inc. (IMVT).
| Event | Form | Date |
|---|---|---|
| Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and...Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | 8-K2.02 | 2026-05-20 |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended...Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | 8-K2.02 | 2026-02-06 |
| Immunovant, Inc.: Corporate updateOn December 10, 2025, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink P... | 8-K8.01 | 2025-12-12 |
| Recent DevelopmentsOn December 10, 2025, Immunovant, Inc. (the “Company”) announced the pricing of an underwritten offering of its common stock, with anticipa... | 8-K8.01 | 2025-12-11 |
| Michael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc....Michael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc. (the “Company”), effective November 21, 2025... | 8-K5.02 | 2025-11-21 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.